Mesenchymal stromal cells from primary osteosarcoma are non‐malignant and strikingly similar to their bone marrow counterparts

抄録

<jats:title>Abstract</jats:title><jats:p>Mesenchymal stromal cells (MSC) are multipotent cells that can be isolated from a number of human tissues. In cancer, MSC have been implicated with tumor growth, invasion, metastasis, drug resistance and were even suggested as possible tumor‐initiating cells in osteosarcoma (OS). However, MSC from OS and their possible tumor origin have not yet been thoroughly investigated. Therefore, primary OS mesenchymal progenitors and OS‐derived MSC were studied. OS samples contained very high frequencies of mesenchymal progenitor cells as measured by the colony‐forming unit fibroblast (CFU‐F) assay (median: 1,117 colonies per 10<jats:sup>5</jats:sup>cells, range: 133–3,000,<jats:italic>n</jats:italic>= 6). This is considerably higher compared to other human tissues such as normal bone marrow (BM) (1.3 ± 0.2 colonies per 10<jats:sup>5</jats:sup>cells,<jats:italic>n</jats:italic>= 8). OS‐derived MSC (OS‐MSC) showed normal MSC morphology and expressed the typical MSC surface marker profile (CD105/CD73/CD90/CD44/HLA‐classI/CD166 positive, CD45/CD34/CD14/CD19/HLA‐DR/CD31 negative). Furthermore, all OS‐MSC samples could be differentiated into the osteogenic lineage, and all but one sample into adipocytes and chondrocytes. Genetic analysis of OS‐MSC as well as OS‐derived spheres showed no tumor‐related chromosomal aberrations. OS‐MSC expression of markers related to tumor‐associated fibroblasts (fibroblast surface protein, alpha‐smooth muscle actin, vimentin) was comparable to BM‐MSC and OS‐MSC growth was considerably affected by tyrosine kinase inhibitors. Taken together, our results demonstrate that normal, non‐malignant mesenchymal stroma cells are isolated from OS when MSC culture techniques are applied. OS‐MSC represent a major constituent of the tumor microenvironment, and they share many properties with BM‐derived MSC.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ